Syntekabio Transfers Five AI-Driven Pipeline Candidates to Panoros Biosciences

On December 16, Syntekabio announced that it had signed a technology transfer agreement with Panoros Biosciences for five antibody candidates intended for the treatment of cancer and immune diseases. This agreement is a concrete outcome of the multi-target antibody joint development memorandum of understanding (MOU) signed by the two companies in early December last year, and marks the first case in which Syntekabio’s AI-based antibody development platform has entered full-scale commercialization.

The antibody candidates covered by this agreement are five out of several cancer and immune disease therapeutics discovered through Syntekabio’s AI-driven Asset Program. These substances were rapidly identified, designed, and optimized using the antibody discovery platform ‘Ab-ARS’ and are regarded as next-generation candidates that overcome the limitations of traditional antibody discovery methods.

According to the terms of the agreement, Syntekabio will physically transfer technical information for the five candidates, and Panoros Biosciences will proceed with actual development and clinical trials for those candidates it decides to license in the future. The two companies explained that this agreement lays the groundwork for mutual cooperation in subsequent development processes, based on the candidates secured at this initial stage of technology transfer.

Panoros Biosciences plans to apply its proprietary platform, ‘αART’ (Alpha Antibody Redesign Technology), to the acquired candidates to develop next-generation antibody therapeutics in multi-antibody formats. The αART technology is a platform that enables precise combination and control of various targets within a single molecule through protein engineering-based structural design. Its technical capabilities have already been demonstrated through the development of the triple-target immuno-oncology drug ‘PB203’.

Syntekabio emphasized the significance of this agreement as the first technology transfer achievement in the antibody field utilizing its Asset Program. The company has expanded the Asset Program to various modalities, including synthetic drugs and antibody drugs, and through this antibody technology transfer, it has further enhanced its prospects for global joint development and technology export.

Jung Jongseon, CEO of Syntekabio, stated, “This meaningful agreement officially confirms the competitiveness of our platform, as our AI-based antibody candidate discovery technology has led to tangible technology transfer results. We will accelerate additional technology transfers and joint development discussions based on the Asset Program to achieve substantial outcomes in the global market.”

Lim Hyesung, CEO of Panoros Biosciences, commented, “By combining Syntekabio’s AI technology with our αART-based multi-target antibody design capabilities, we will be able to establish a next-generation antibody therapeutic pipeline with high therapeutic value.” He added, “We will swiftly advance the production and in-vitro efficacy evaluation of the triple-target candidates to achieve visible development milestones.”